# LITESPARK-013 (NCT04489771)

> A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

No report yet. It can be ordered.

- Drugs tested: belzutifan
- Indication: advanced clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04489771
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Renal Cell
- Interventions: Belzutifan
- Enrollment: 154
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on LITESPARK-013 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 25
- Podcasts: 3
- YouTube: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=litespark-013-nct04489771

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04489771", "email": "<work email>"}; the inbox owner confirms by the emailed link.